Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Two truncating variants in FANCC and breast cancer risk

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Development of a downstream process for the production of an inactivated whole hepatitis C virus vaccine

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Glycemic control and use of glucose-lowering medications in hospital-admitted type 2 diabetes patients over 80 years

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Simvastatin improves mitochondrial respiration in peripheral blood cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Low high-density lipoprotein and increased risk of several cancers: 2 population-based cohort studies including 116,728 individuals

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Clinical value of serum hyaluronan and propeptide of type III collagen in patients with pancreatic cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Tocilizumab and soluble interleukin-6 receptor in JAK2V617F somatic mutation and myeloproliferative neoplasm

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Transcriptome-wide association study reveals candidate causal genes for lung cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  • ABCTB Investigators
View graph of relations

Fanconi anemia (FA) is a genetically heterogeneous disorder with 22 disease-causing genes reported to date. In some FA genes, monoallelic mutations have been found to be associated with breast cancer risk, while the risk associations of others remain unknown. The gene for FA type C, FANCC, has been proposed as a breast cancer susceptibility gene based on epidemiological and sequencing studies. We used the Oncoarray project to genotype two truncating FANCC variants (p.R185X and p.R548X) in 64,760 breast cancer cases and 49,793 controls of European descent. FANCC mutations were observed in 25 cases (14 with p.R185X, 11 with p.R548X) and 26 controls (18 with p.R185X, 8 with p.R548X). There was no evidence of an association with the risk of breast cancer, neither overall (odds ratio 0.77, 95%CI 0.44-1.33, p = 0.4) nor by histology, hormone receptor status, age or family history. We conclude that the breast cancer risk association of these two FANCC variants, if any, is much smaller than for BRCA1, BRCA2 or PALB2 mutations. If this applies to all truncating variants in FANCC it would suggest there are differences between FA genes in their roles on breast cancer risk and demonstrates the merit of large consortia for clarifying risk associations of rare variants.

Original languageEnglish
JournalScientific Reports
Volume9
Issue number1
Pages (from-to)12524
ISSN2045-2322
DOIs
Publication statusPublished - 29 Aug 2019

ID: 59350783